BELLUS Health is a clinical stage biotechnology company developing novel therapeutics for the treatment of chronic cough and other chronic disorders triggered by hypersensitization. The Company’s lead product candidate, BLU-5937, is a highly selective P2X3 antagonist being developed for the treatment of chronic cough and chronic pruritus. P2X3 receptors are channels expressed in sensory nerves throughout the body and play an important role in the sensitization of the nervous system to various stimuli. BELLUS is exploring how P2X3 activation contributes to irritation and pain, and whether inhibition of P2X3 receptors can help treat other afferent hypersensitization-related disorders. BELLUS Health is based in Laval, Quebec and its shares trade under the ticker BLU on both Nasdaq and the Toronto Stock Exchange.
Location: Canada, Quebec, Laval
Employees: 51-200
Total raised: $270M
Founded date: 1993
Investors 1
| Date | Name | Website |
| - | adMare Bio... | admarebio.... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 17.12.2021 | - | $200M | - |
| 09.09.2019 | - | $70M | - |
Mentions in press and media 16
| Date | Title | Description |
| 21.12.2021 | BELLUS Health : Corporate Presentation – December 2021 | Investor Presentation NASDAQ/TSX - BLU December 21st, 2021 Forward Looking Statements Certain statements contained in this presentation, other than statements of fact that are independently verifiable at the date hereof, may constitute &quo... |
| 18.12.2021 | BELLUS Health : Closes US$200 Million Public Offering of Common Shares in Canada and the United States - Form 6-K | BELLUS Health Closes US$200 Million Public Offering of Common Shares in Canada and the United States LAVAL, Quebec, December 17, 2021 - BELLUS Health Inc. (NASDAQ: BLU)(TSX: BLU) (the "Company" or "BELLUS Health") announ... |
| 17.12.2021 | BELLUS Health Closes US$200 Million Public Offering of Common Shares in Canada and the United States | - |
| 17.12.2021 | BELLUS Health Closes US$200 Million Public Offering of Common Shares in Canada and the United States | BELLUS Health Inc. (NASDAQ: BLU)(TSX: BLU) (the “Company” or “BELLUS Health”) announced today that it has completed its previously-announced underwritten public offering in Canada and the United States (the “Offering”) of 25,000,000 common ... |
| 15.12.2021 | BELLUS Health Announces Pricing of US$200 Million Public Offering in Canada and the United States | In connection with its previously announced public offering of common shares in Canada and the United States (the “Offering”), BELLUS Health Inc. (“BELLUS Health” or the “Company”) (TSX and Nasdaq: BLU) today announced that it has entered i... |
| 14.12.2021 | BELLUS Health Announces the Launch of a Public Offering of Common Shares in Canada and the United States | BELLUS Health Inc. (“BELLUS Health” or the “Company”) (TSX and Nasdaq: BLU), announced today the filing of a preliminary prospectus supplement (the “Supplement”) to its short form base shelf prospectus dated December 23, 2020 (the “Base Pro... |
| 01.11.2021 | Corporate Presentation – November 2021 | Investor Presentation NASDAQ/TSX - BLU November 1, 2021 Forward Looking Statements Certain statements contained in this presentation, other than statements of fact that are independently verifiable at the date hereof, may constitute "f... |
| 12.08.2021 | UPDATED: FDA says it needs a little more time to decide on Merck's P2X3 for chronic cough | A few months ago, Merck emerged as a clear leader among a group of drugmakers racing through the clinic with a new class of therapies for chronic cough. But it looks like the Kenilworth, NJ-based pharma will now be taking another lap. The F... |
| 24.03.2021 | BELLUS Health Appoints William Mezzanotte, MD, MPH to its Board of Directors | LAVAL, Quebec--(BUSINESS WIRE)--Mar 24, 2021-- BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and othe... |
| 22.10.2020 | BELLUS Health Closes US$40 Million Public Offering of Common Shares in Canada and the United States, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares | - |
Show more